-- IFM to receive $310 million upfront, with up to $1.265 billion in milestones for a total of $1.575 billion BOSTON, April 1, 2019 /PRNewswire/ -- IFM Therapeutics (IFM), a privately held ...
Milestone marks the third major acquisition for an IFM Therapeutics subsidiary in the past seven years The acquisition provides Novartis with full rights to IFM Due's portfolio of STING antagonists, ...
BOSTON, April 1, 2019 /PRNewswire/ -- IFM Therapeutics (IFM), a privately held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, ...
BOSTON, March 13, 2024 /PRNewswire/ -- IFM Therapeutics (IFM), a privately held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results